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Introduction  
Recurrent vulvovaginal candidiasis infection  
is considered as the incidence of at least 3 or 
4 independent   vulvovaginal     candidiasis  
infection with specific clinical symptoms 
and laboratory confirmation (positive smear 
or  culture)  in a year that doesn't have to do 
with antibiotic therapy (1-6).  
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The highest prevalence of this disease is in 
women in the ages of 35-25 years. The 
prevalence of this infection has been 
reported in different communities (7). 
There is no doubt that diabetes mellitus with 
bad control is a causes of vulvovaginal 
candidiasis infection (8-9). The possible 
relationship between recurrent candidiasis 
vaginal infection and glucose uptake has 
been the subject of a suspicious for years 
(10-13).  
Study of Denders et al. on 60 patients and 30 
controls confirmed sugar metabolism 
disorders in people with recurrent 
candidiasis vaginal infection. 
Yang et al. showed that the prevalence of 
vulvovaginal candidiasis infection were 
considerably higher in women with GDM 
and GIGT (15.3% and 17.4% respectively) 
compared to the control group (7.2%) (14). 
Excessive growth of Candida might be as a 
result of inhibition of natural vaginal flora 
bacteria, reducing local cellular immunity, 
changes in metabolic and nutritional 
environment and vagina mechanisms (15).  
Numerous factors cause increase of 
infections including pregnancy, 
consumption of gestational tablets 
containing high estrogen (more than 40 µg), 
IUD, taking antibiotics, uncontrolled 
diabetes and immunosuppressive drugs, 
AIDS, wearing tight underwear, 
uncircumcised men, use of diaphragm, 
repeated vaginal shower, unhealthy or 
abundant sexual relationships, chronic 
anemia and seasonal allergy (16-20). 
Wang et al believe that there is no 
communication between economic and 
social conditions with vaginitis (21). 
Clotrimazole is regarded as the first 
treatment and in the event of failure to 
response, Fluconazol is used (22-23). This 
drug has uncommon and unsuitable side 
effects like other drugs such as mild 
digestive intolerance, headaches and skin 
rashes (24). 
Probiotic are live microorganisms with 
positive health effects when they are 
consumed by the host (25). Lactobacillus is 
a natural resident of flora vagina having 
basic role in suppressing the potential 
pathogen. Lactobacillus which is prescribed 
to the genital path has important part as 
prophylaxis in improving and strengthening 
the defense of genital micro flora against 
bacterial infections (26). 
There exist different kinds of probiotic and 
lactobacillus and bifidobacterium are two 
major groups of them (27-28). Some of 
these studies have shown that probiotic 
lactobacilli are highly effective in the 
treatment of candidiasis vulvovaginal (26, 
29). 
While, others do not endorse this report and 
the positive influences of probiotic in the 
treatment of candidiasis vulvovaginal is still 
controversial (30-31). The aim of this study 
was to evaluate the effect of probiotic 
therapy in patients with candidiasis vaginitis 
compared with the standard treatment. 
Materials and methods  
In a double-blind randomized clinical trial  
which  was performed on women with 
recurrent vaginitis candidiasis in Department 
of Obstetrics and Gynecology of Qazvin 
University of Medical Sciences and 
Department of infectious diseases of Tabriz 
University of medical sciences,  recurrent  
vaginitis  candidiasis  infection status  
(resistant to treatment and relapse more 
than 3 times) and the responses to 
therapy in the patients were evaluated. 
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In this study, all women with the symptoms 
of Candida vaginitis who had referred for 
treatment during the study were selected and 
entered the study. The sample size necessary 
to compare the two groups was calculated 
82 persons with 95 percent confidence 
interval. Samples were determined founded 
on "target based sampling method» among 
qualified individuals and then were divided 
into two groups (case and control) of 
41 people using Random allocation  
software.  
Samples were investigated for examination 
and sampling based on 
inclusion criteria including having the age 
range of 15-45 years, being married, the 
existence of symptoms and Candida 
vaginitis symptoms and signs in interview 
and observation and confirmation via 
laboratory studies, being monogamy, non-
pregnant, non-lactating, non-menopause, not 
using pills for pregnancy prevention, the 
lack of any known disease, not 
using antibiotics in the last two weeks, 
not using oral and vaginal medications 
related to vaginal infection  treatment 
during the last two-weeks, the lack 
of any sensitivity to the drugs used, the 
lack of trichomoniasis vaginitis and also 
completing the consent form.   
Researcher and patients were blind other 
than case study group (case and control). 
Necessary information was obtained from 
patients and was recorded 
including demographic information  
(age, weight and  BMI), obstetrical  
information  (gravidity and parity) and the 
status of disease (itching and  vaginal  
secretions).  
Qualified individuals went under 
lithotomy position and speculum was 
inserted into vagina without any lubricant 
impregnation. At first, cervix and vagina 
were assessed in terms of symptoms such 
as (viscosity and smell of secretions,  
erythema and redness of vulvovaginal, 
lesions of pustulopapuler and volvo 
etc.) and abnormal findings and recorded in 
the observations check list. Then samples of 
secretions were collected from upper part 
and the lateral wall of the vagina with the 
use of three sterile cotton swaps and were 
examined.  
The Ph of the vagina was determined using 
the PH meter (Merck, Germany). Ph 
of secretions upper than 4.5 was indicative 
of mixed infection and samples 
were excluded.  
Patients were entered the 
study after approval of a Candida vaginitis 
infection. Patients in both groups 
were treated with capsule Fluconazol 100 
mg /BID for seven days and vaginal 
probiotic capsules was prescribed for 
patients in case group for two week after 
treatment.   
In this study both groups treated with 
vaginal cream of Clotrimazole 1% to the 
extent of a plastic applicator for each  
night for a week. All the samples were 
given a health  educational  pamphlet  
including instructions  of how to consume 
drug, drug side effects, health  advices, lack 
of taking antibiotics and other vaginal  
medications.  
Exclusion criteria in this study includes  
occurrence of pregnancy, lack of desire 
of the person to continue participation in 
the study, indication of using antibiotics for 
any cause during the study, the incidence of 
intolerance or allergic to any  medications,  
failure to observe target tips in this study.   
Both groups checked in matter of response 
to therapy (clinical symptoms, PH values, 
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microscopic assessment and culture of 
sabro-Dextrose-Agar medium) a week 
after completion of the course of 
treatment and the results were recorded.  
Definitive diagnosis was carried 
out using KOH solution. Patients with more 
than 3 times of infection in a year were 
considered as current vaginitis.  
Reoccurrence symptoms within 2 months  
after treatment with laboratory  confirmation  
were considered as recurrence of the 
disease. Diabetic patients and patients 
with HIV were excluded from the study. 
Result and Discussion 
In this study, 82 patients with recurrent  
vulvovaginal candidiasis were selected 
and treated in two groups of case and 
control. The mean age of the patients was 
27.09±4.43 and 28.21±7.11 years in the case 
and control group, respectively (P = 0.394). 
Demographic finding of patients in two 
groups were shown in table I.  
There existed clinical symptoms 
and complaints of the patients at admission 
including itching in 93.9% of cases (40 
patients in case group and 37 patients in 
control group), vulvovaginal burning in 
79.2% of cases(34 patients in case group and 
31 patients in control group), disuria 
in 37.8% of cases(17 patients in case group 
and 14 patients in control group), 
dyspareunia  in 59.75% of cases(26 patients 
in case group and 23 patients in control 
group), abnormal vaginal discharges in 
79.2% cases(32 patients in case group and 
33 patients in control group) and deep pelvic 
pain in 64.6% of cases(28 patients in case 
group and 25 patients in control group).  
Although, there existed clinical symptoms 
and complaints of the  patients  after 
treatment  including itching in 59.75% of 
cases(18 patients in case group and 31 
patients in control group), vulvovaginal 
burning in 14.6% of cases(3 patients in case 
group and 9 patients in control group), 
disuria in 18.3% of cases(4 patients in case 
group and 11 patients in control group), 
dyspareunia in 36.6% of cases(9 patients in 
case group and 21 patients in control group), 
abnormal discharges in 50% of cases(15 
patients in case group and 26 patients in 
control group) and deep pelvic pain in 30% 
of cases(8 patients in case group and 17 
patients in control group).  
There existed significant differences in the 
case and control groups before treatment 
in matters of symptoms. These symptoms 
included itching (P=0.359), vulvovaginal 
burning (P=0.414),  disuria  (P=0.494),  
dyspareunia (P=0.499), abnormal vaginal 
discharges (P=0.785), as well as deep pelvic 
pain (P=0.488). Patients in the case group 
were significantly lower than control group 
in the case of some symptoms after 
treatment such as frequency and the 
intensity of the itching (P=0.003),  disuria  
(P=0.046),  dyspareunia (P=0.006), 
abnormal vaginal discharges (P=0.015) and  
deep  pelvic pain (P=0.031), while 
frequency  of vulvovaginal burning 
after treatment had no important difference 
between two groups (P=0.061). The severity 
and frequency of symptoms in patients of 
case group had been reduced after treatment; 
however these changes were not significant 
in the control group (table II). 
At the end of the study, 3 patients from case 
group and 11 patients of control group had 
shown no responses to the treatment 
and their disease intensified.  
The intensifying rate and lack of response 
to treatment in patients of case group (under 
the supplemental  treatment  with the  
probiotic)  were  significantly lower than 
patients  in control group (P = 0.019). 
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Table.I Demographic finding of patients in two groups  
Group 
Case Control Total P 
Age 27.10 ± 4.44 28.22 ± 7.11 27.66 ± 5.92 0.394 
Weight 59.16 ± 14.01 61.17 ± 15.15 60.16 ± 14.54 0.534 
BMI 21.81 ± 3.40 22.09 ± 3.80 21.95 ± 3.59 0.727 
Parity 2.46 ± 1.12 2.12 ± .87 2.29 ± 1.01 0.127 
Gravidity 3.72 ± 1.23 3.64 ± 1.12 3.68 ± 1.17 0.792 
 
Table.II  Evaluation of patient s symptoms between two groups  
Group 
Case Control  
Before After P Before After P 
Itching 40 18 <0.001 37 31 0.058 
Vulvovaginal Burning 34 3 <0.001 31 9 <0.001 
Disuria 17 4 <0.001 14 11 0.083 
Dyspareunia 26 9 <0.001 23 21 0.157 
Abnormal Vaginal 
Discharges 
32 15 <0.001 33 26 0.008 
Deep Pelvic Pain 28 8 <0.001 25 17 0.005 
Martinez et al. said that 55 people (100%) 
had complaints with vaginal secretion 
accompanied by at least one symptom of 
vaginal irritation, itching, dysuria and 
dysparoni in both groups of therapy with 
Fluconazol and probiotic, as well as 
Fluconazol and placebo, while after 
treatment, only 3 people (10.3%) in group of 
Fluconazol and probiotic therapy and 9 
people (34.6%) in group of Fluconazol and 
placebo had complaints with vaginal 
secretion accompanied by at least one 
symptom of vaginal irritation, itching, 
disuria and dyspareunia (P=0.03) (29). 
The results showed that both methods of 
therapy have been effective in resolving the 
symptoms of patients and have been the 
same. 
In our study, the most common complaint of 
patients after the treatment was reported as 
itching (43.9%) and  abnormal  vaginal  
discharge  (36.6%). Additionally, itching  
(75.6%)  and abnormal vaginal  discharge  
(63.4 %) were also the most common 
complaints of patients in the control group. 
Ride et al. expressed that improvement of 
symptoms was seen in 12 persons (30%) 
treated with oral lactobacillus such as 
ramunosos and fermentom compared with 
the group treated with placebo which were 4 
people (12%) which was indicative of 
potential effectiveness of ramunosos and 
fermentom (32). 
Martinez et al. showed that after treatment 
only 2 people (6.9%) in group of therapy 
with Fluconazol and probiotic and 1 person 
(3.8%) in group of Fluconazol and placebo 
therapy have had PH > 4.5 (29). 
Martinez et al. also suggested that 55 people 
(100%) in both groups had a positive culture 
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of candida before the treatment. After 
treatment, only 3 people (10.3) in group 
treated ith Fluconazol and probiotic and 10 
people (38.5%) in group of therapy with 
Fluconazol and placebo had a positive 
culture of Candida (29). 
Srees et al expressed that lactobacillus 
secreting large quantities of H2O2, inhibit 
the growth of albicans candida faster and 
stronger than other species (33). 
As with the results of the above studies, the 
use of probiotic compounds along with  
other  ordinary treatments improves 
symptoms  and the success rate of treatment 
in the treatment of patients 
with recurrent vulvovaginal candidiasis.  
Conclusion  
The results of the present study showed that 
a combined treatment using probiotic 
materials in addition to the use 
of routine treatments is effective for 
patients with recurrent recurrent vulvovagin
al candidiasis. This combines strategy leads 
to increased response of patients to  
treatment and dramatically reduction 
of frequency and severity of symptoms in  
patients, so as to the frequency and severity 
of these symptoms was lower in case 
compared to the control group after the 
treatment.  
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